Since mutations of genes in the RAS–RAF–MEK–ERK and PI3K/Akt/PTEN/mTOR pathways, as well as TP53 and APC, are predominantly involved in CRC treatment response [4], we wanted to examine whether the mutation profiles of the genes in these pathways may be used to predict treatment response. This evidence concerns the gene APC and colorectal carcinoma.